66
Participants
Start Date
December 1, 2024
Primary Completion Date
December 1, 2026
Study Completion Date
December 31, 2026
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Ruijin Hospital
OTHER